Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1167 in healthy adult participants
NCT07266818Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial comparing MK-1167 with Placebo (2 arms). Primary endpoints: Number of Participants Who Experience an Adverse Event at 9 weeks and Number of Participants Who Discontinue Study Treatment Due to an AE at 1 week. Started Dec 2025; status: completed.
02
Drugs
MK-1167
Beyond the preview
Go deeper on NCT07266818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266818.